Laboratory Corporation of America Holdings (LH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Laboratory Corporation of America Holdings stock (LH) is currently trading at $266.02. Laboratory Corporation of America Holdings PE ratio is 25.44. Laboratory Corporation of America Holdings PS ratio (Price-to-Sales) is 1.58. Analyst consensus price target for LH is $307.71. WallStSmart rates LH as Hold.
- LH PE ratio analysis and historical PE chart
- LH PS ratio (Price-to-Sales) history and trend
- LH intrinsic value — DCF, Graham Number, EPV models
- LH stock price prediction 2025 2026 2027 2028 2029 2030
- LH fair value vs current price
- LH insider transactions and insider buying
- Is LH undervalued or overvalued?
- Laboratory Corporation of America Holdings financial analysis — revenue, earnings, cash flow
- LH Piotroski F-Score and Altman Z-Score
- LH analyst price target and Smart Rating
Laboratory Corporation of America Holdings
📊 No data available
Try selecting a different time range
LH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Laboratory Corporation of America Holdings (LH)
LH is trading near its Graham intrinsic value of $333.88, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Laboratory Corporation of America Holdings (LH) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, price/sales. Fundamentals are solid but monitor weak areas for improvement.
Laboratory Corporation of America Holdings (LH) Key Strengths (4)
100.36% of shares held by major funds and institutions
Large-cap company with substantial market presence
Good growth relative to its price
Paying $1.58 for every $1 of annual revenue
Supporting Valuation Data
Laboratory Corporation of America Holdings (LH) Areas to Watch (6)
Thin operating margins with cost pressures present
Modest revenue growth at 5.60%
Thin profit margins with limited profitability
Moderate profitability with room for improvement
Fairly priced relative to book value
Solid earnings growth at 15.70%
Supporting Valuation Data
Laboratory Corporation of America Holdings (LH) Detailed Analysis Report
Overall Assessment
This company scores 63/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.8/10) while 6 fall into concern territory (avg 4.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap, PEG Ratio. Valuation metrics including PEG Ratio (1.10), Price/Sales (1.58) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Profit Margin. Some valuation metrics including Price/Book (2.54) suggest expensive pricing. Growth concerns include Revenue Growth at 5.60%, EPS Growth at 15.70%, which may limit upside. Profitability pressure is visible in Return on Equity at 10.50%, Operating Margin at 10.50%, Profit Margin at 6.28%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 10.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 5.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Market Cap) and negatives (Operating Margin, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LH's Price-to-Sales ratio of 1.58x sits near its historical average of 1.41x (79th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 14% below its historical high of 1.84x set in Feb 2007, and 70% above its historical low of 0.93x in Jan 2019.
WallStSmart Analysis Synopsis
Data-driven financial summary for Laboratory Corporation of America Holdings (LH) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Laboratory Corporation of America Holdings operates as a stable business with moderate growth and solid fundamentals. Revenue reached 14.0B with 6% growth year-over-year. Profit margins are thin at 6.3%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 1050.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 490M in free cash flow and 614M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Laboratory Corporation of America Holdings push profit margins above 15% as the business scales?
Debt management: total debt of 7.2B is significantly higher than cash (532M). Monitor refinancing risk.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Laboratory Corporation of America Holdings.
Bottom Line
Laboratory Corporation of America Holdings offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(182 last 3 months)
| Insider | Type | Shares |
|---|---|---|
SCHECHTER, ADAM H Director, President & CEO | Sell | -8,705 |
| Insider | Type | Shares |
|---|---|---|
VAN, DER VAART SANDRA D EVP, Corporate Affairs | Sell | -547.54 |
| Insider | Type | Shares |
|---|---|---|
CAVENEY, BRIAN J EVP, Pres of ED, CMO & CSO | Sell | -1,500 |
| Insider | Type | Shares |
|---|---|---|
WILKINSON, PETER J SVP, Chief Accounting Officer | Sell | -666 |
| Insider | Type | Shares |
|---|---|---|
MELTZER, JONATHAN C EVP, Operations | Sell | -87 |
Data sourced from SEC Form 4 filings
Last updated: 8:24:19 AM
About Laboratory Corporation of America Holdings(LH)
NYSE
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories.